TY - JOUR
T1 - The Gene-Drug Duality
T2 - Exploring the Pharmacogenomics of Indigenous Populations
AU - Nagaraj, Shivashankar H.
AU - Toombs, Maree
N1 - Funding Information:
Funding for this research was supported by the MRFF Genomics Health Futures Mission grant (76757).
Publisher Copyright:
© Copyright © 2021 Nagaraj and Toombs.
PY - 2021/9/20
Y1 - 2021/9/20
N2 - While pharmacogenomic studies have facilitated the rapid expansion of personalized medicine, the benefits of these findings have not been evenly distributed. Genomic datasets pertaining to Indigenous populations are sorely lacking, leaving members of these communities at a higher risk of adverse drug reactions (ADRs), and associated negative outcomes. Australia has one of the largest Indigenous populations in the world. Pharmacogenomic studies of these diverse Indigenous Australian populations have been hampered by a paucity of data. In this article, we discuss the history of pharmacogenomics and highlight the inequalities that must be addressed to ensure equal access to pharmacogenomic-based healthcare. We also review efforts to conduct the pharmacogenomic profiling of chronic diseases among Australian Indigenous populations and survey the impact of the lack of drug safety-related information on potential ADRs among individuals in these communities.
AB - While pharmacogenomic studies have facilitated the rapid expansion of personalized medicine, the benefits of these findings have not been evenly distributed. Genomic datasets pertaining to Indigenous populations are sorely lacking, leaving members of these communities at a higher risk of adverse drug reactions (ADRs), and associated negative outcomes. Australia has one of the largest Indigenous populations in the world. Pharmacogenomic studies of these diverse Indigenous Australian populations have been hampered by a paucity of data. In this article, we discuss the history of pharmacogenomics and highlight the inequalities that must be addressed to ensure equal access to pharmacogenomic-based healthcare. We also review efforts to conduct the pharmacogenomic profiling of chronic diseases among Australian Indigenous populations and survey the impact of the lack of drug safety-related information on potential ADRs among individuals in these communities.
KW - adverse drug reaction
KW - chronic disease
KW - indigenous health
KW - personalized medicine
KW - pharmacogenomics
UR - http://www.scopus.com/inward/record.url?scp=85116505515&partnerID=8YFLogxK
U2 - 10.3389/fgene.2021.687116
DO - 10.3389/fgene.2021.687116
M3 - Short survey
AN - SCOPUS:85116505515
VL - 12
SP - 1
EP - 6
JO - Frontiers in Genetics
JF - Frontiers in Genetics
SN - 1664-8021
M1 - 687116
ER -